Clinical trials: Cerebral Small Vessels Disease
Fabry Disease
A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
- Trial name
- NCT00214500
- Testing
- migalastat HCl
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Amicus Therapeutics
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed study medication treatment in the lead-in study TIS6463-203.
- Trial name
- NCT06961344
- Testing
- zagociguat 15mg
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 37 people
- Sponsor
- Tisento Therapeutics
Fabry Disease, Neuropathic Pain
Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease
The purpose of this study is to determine efficacy of gabapentin vs. placebo at controlling peripheral neuropathic pain in patients with Fabry disease, and reducing their use of opioid analgesics.
- Trial name
- NCT01588314
- Testing
- Gabapentin
- Where
- United States
- Sponsor
- University of Minnesota
Cerebral Microbleeds, Congenital Haemophilia, Congenital Von Willebrand Disease
Severe Congenital Hemostatic Defects, Cerebral MIcrobleeds and COGnition
Cerebral microbleeds (CMBs) are haemosiderin deposits, resulting from the leakage of erythrocytes from small cerebral vessels, which can be detected noninvasively using susceptibility-sensitive magnetic resonance imaging (MRI)…
- Trial name
- HEMICOG (NCT06090201)
- Testing
- 3-Tesla brain MRI and a comprehensive neuropsychological assessment
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Lille
Cerebral Small Vessel Diseases
Effect of Multifunctional Nutrition Tube on Cerebral Small Vessel Disease Patients
Nasogastric tube feeding (NGT) has been widely used in cerebral small vessel disease (CSVD) patients with dysphagia but has a significant risk of complications.
- Trial name
- NCT06328842
- Testing
- Intermittent Oro-esophageal Tube Feeding, Nasogastric Tube Feeding
- Volunteers
- 88 people
- Sponsor
- Copka Sonpashan
Infectious Metabolic Encephalopathy, Ischemic Stroke
Procedural Motor Memory in Long COVID-19
Background: Most people who get COVID-19 seem to recover with no long-term effects. However, some people who recover from acute COVID-19 infections report lingering symptoms. This is called long COVID.
- Conditions
- Infectious Metabolic Encephalopathy, Ischemic Stroke, Seizure, Viral Encephalitis, Small and Large Vessel
- Trial name
- NCT05746624
- Testing
- keypresses
- Where
- United States
- Volunteers
- 333 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Fabry Disease
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
Fabry Disease (FD) is a rare X-linked lysosomal storage disorder (LSD) caused by mutations in the GLA gene which translates into decreased activity or lack of function of the enzyme alpha-galactosidase A (α-GAL A) and…
- Trial name
- NCT03228940
- Testing
- RVX000222
- Where
- Canada
- Sponsor
- Resverlogix Corp
Fabry Disease, Fabry Disease, Cardiac Variant
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score
This study aims to evaluate the prevalence of Fabry Disease (FD) among a cohort of high risk patients with left ventricular hypertrophy (LVH) presenting at the University Hospital Würzburg over the last 20 years.
- Conditions
- Fabry Disease, Fabry Disease, Cardiac Variant, Lysosomal Storage Diseases, HCM - Hypertrophic Cardiomyopathy
- Trial name
- FAPREV-HCM (NCT04943991)
- Testing
- blood sampling (alpha-Galactosidase & LysoGb3)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Wuerzburg University Hospital
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Enpowering Progression Risk of Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, and other clinical…
- Trial name
- PRIORITY (NCT06960538)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Acute Ischemic Stroke, Haemorrhagic Stroke
Translational Immunodiagnostics in Stroke (TrImS)
In adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim: 1. to identify early brain- and pathology-specific circulating, whole blood, plasma and serum panorOmic…
- Conditions
- Acute Ischemic Stroke, Haemorrhagic Stroke, Transient Ischemic Attacks, Cardioembolic Stroke
- Trial name
- TrImS (NCT05300997)
- Testing
- Biomarker blood draw and saliva collection
- Where
- China
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Alzheimer's Disease, Small Vessel Disease White Matter Hyperintensities Subtype
Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease
The prevalence of both Alzheimer's Disease (AD) and stroke doubles each decade over 65 years old. Both are major causes of dementia, currently estimated to affect 46 million people worldwide.
- Conditions
- Alzheimer's Disease, Small Vessel Disease White Matter Hyperintensities Subtype, Vascular Cognitive Impairment
- Trial name
- MITNEC C6 (NCT02330510)
- Where
- 8 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Dr. Sandra E Black
Intracerebral Hemorrhage
Minimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage--Small Hemorrhage Evacuation (MIRACLE-S)
The objective of this study is to determine whether minimally invasive soft channel brain hemorrhage evacuation (scMIS), compared to usual care, leads to superior functional recovery as measured by utility-weighted modified…
- Trial name
- MIRACLE-S (NCT06688162)
- Testing
- Usual Care, Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Capital Medical University
ANCA-associated Vasculitis
Abatacept in ANCA Associated Vasculitis
The purpose of this study is to investigate whether abatacept can prevent relapse in patients with ANCA associated vasculitis(AAV). This is a randomised double blinded placebo controlled trial.
- Trial name
- ABAVAS (NCT00482066)
- Testing
- Abatacept (Orencia)
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Imperial College London
Cerebral Small Vessel Disease, Repetitive Transcranial Magnetic Stimulation (rTMS)
Effect of High Frequency Cerebellar Repetitive Transcranial Magnetic Stimulation on Functional Ambulation of Patients With Cerebral Small Vessel Disease
This study aims to evaluate the effect of repetitive transcranial magnetic stimulation (rTMS) applied over the cerebellum on gait performance and balance in patients with cerebral small vessel disease (CSVD).
- Conditions
- Cerebral Small Vessel Disease, Repetitive Transcranial Magnetic Stimulation (rTMS), Balance, Gait Disorders
- Trial name
- NCT07531797
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
CADASIL, CADASIL (Diagnosis)
RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)
Cerebrovascular diseases (CVDs) are one leading cause of morbidity and mortality worldwide. Despite intensive investigations, more than 30% of strokes remain of undetermined origin.
- Conditions
- CADASIL, CADASIL (Diagnosis), Moya Moya Disease, Moyamoya
- Trial name
- ALIGNED (NCT06935578)
- Where
- 17 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Alzheimer Disease, Dementia, Vascular
Cerebral Vascular Reserve in Small Vessel Disease and Alzheimers Disease
Alzheimers disease and cerebral small vessel disease have a considerably overlap in patients and have common risk factors. The diseases are difficult to separate in individual patients and we hypothesize that a reduced cerebral…
- Trial name
- NCT05443308
- Testing
- Cerebral [15O]H2O PET before and after diamox infusion
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Melphalan in Patients With Neoplastic Meningitis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of melphalan in patients with persistent or recurrent…
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00002750
- Testing
- melphalan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Stroke, Acute
Mobile MRI for Immediate Radiological Acute Cerebral Lesion Evaluation in Stroke
This prospective observational study will evaluate the potential value of mobile MRI in patients with suspected or proven acute stroke and Transient Ischemic Attack (TIA), undertaking additional imaging in the emergency…
- Trial name
- MIRACLES (NCT06262217)
- Testing
- Mobile MRI scanner
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- NHS Greater Glasgow and Clyde
Acute Ischemic Stroke
CompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing Cerebral infarctioN
Progressing stroke is associated poor functional outcome and neurological deficit. Currently, no treatment for progressing stroke is recommended on the guideline. Carbogen is a mixture of 5% CO2 with 95% O2.
- Trial name
- NCT06770426
- Testing
- carbogen with or without phenyleprhine, phenylephrine
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University